COMMUNIQUÉS West-GlobeNewswire

American Addiction Centers Names Greenhouse Treatment Center a Veterans Center of Excellence
20/05/2024
GRAND PRAIRIE, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- American Addiction Centers (AAC) has recognized Greenhouse Treatment Center as a Veterans Center of Excellence, highlighting its commitment to providing high- [...]
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
20/05/2024
OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM Chief Executive Officer Thomas K. Equels will participate in two upcoming investor [...]
Helius Medical Technologies, Inc. Announces PoNS® Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts
20/05/2024
-- Approval provides U.S. veterans and other U.S. government agency employees who suffer gait and balance impairment due to multiple sclerosis (MS) access to the only portable neurostimulation therapy with the potential [...]
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
20/05/2024
Granted Indian Patent for its MyoVista® Wavelet Technology Southlake, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), [...]
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
20/05/2024
Compared to controls, mice treated with GRI-0621 showed improved fibrosis and immunopathology; Inhibition of type 1 invariant Natural Killer T (iNKT) cell activity led to a decrease in fibrosis score and total lung [...]
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
20/05/2024
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the [...]
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
20/05/2024
Waiver confirms that paediatric studies of certepetide in pancreatic cancer are not needed Significant clinical trial burden and costs avoided due to waiver BASKING RIDGE, N.J., May 20, 2024 (GLOBE NEWSWIRE) -- Lisata [...]
Nanox to Report First Quarter and Financial Results on May 28, 2024
20/05/2024
PETACH TIKVA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it will report its financial [...]
LIXTE Biotechnology Holdings Provides Update on Recent Activities
20/05/2024
Publishing of Findings in Recent Pre-Clinical Study for LIXTE’s Proprietary Compound, LB-100, in New Field of Cancer Biology, “Activation Lethality” Presentation at MedInvest Biotech and Pharma Investor Conference Co- [...]
ONCOTELIC TO PARTICIPATE AT THE ASCO 2024 MEETING
20/05/2024
AGOURA HILLS, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its Chief Clinical Officer- Dr. Anthony Maida will be participating at the ASCO 2024 meeting. Abstract: [...]
NKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s Disease
20/05/2024
SNK01, a cryopreserved, autologous enhanced natural killer cell therapy, delivered in highest dose to date, demonstrates preliminary clinical benefit without any drug-related adverse events. Company advances SNK01 into [...]
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
20/05/2024
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to [...]
Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
20/05/2024
Mainz Biomed Presented Industry Leading Results: 97% Sensitivity for Colorectal Cancer, 82% for Advanced Precancerous Lesions The eAArly DETECT results demonstrated that within the advanced precancerous lesion patients [...]
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
20/05/2024
Boston (May 20, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced [...]
APRINOIA Therapeutics Announces Fast Track Designation Granted by U.S. FDA to APN-1607 (florzolotau) for the Diagnosis of Progressive Supranuclear Palsy
20/05/2024
Fast Track Designation follows announcement in January 2024 that the U.S. Food and Drug Administration (FDA) granted a “Study May Proceed” letter for Aprinoia’s planned Phase 3 study of APN-1607 (florzolotau) in the U.S [...]
Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X Syndrome
20/05/2024
Receiving Orphan Drug Designation for SPG601 emphasizes the pressing demand for novel therapies for individuals living with Fragile X Syndrome SAN DIEGO, May 20, 2024 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical- [...]
InnovAge Welcomes John Koehn as Senior Vice President of External Affairs
20/05/2024
DENVER, May 20, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to dual-eligible seniors through the Program of All- [...]
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
20/05/2024
Management and scientific/medical thought leaders to discuss topline overall survival data from phase 2 clinical trial of CAN-2409 in NSCLC NEEDHAM, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. ( [...]
PolarityTE Secures $22.5 Million Financing to Advance SkinTE Phase III Pivotal Study in Diabetic Foot Ulcers
20/05/2024
SALT LAKE CITY, May 20, 2024 (GLOBE NEWSWIRE) -- PolarityTE, a clinical-stage biotechnology company developing regenerative tissue products, today announced that it has raised $12.5 million in equity financing from [...]

Pages